Navigation Links
ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
Date:12/31/2008

EXTON, Pa., Dec. 31 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the 27th Annual J.P. Morgan Healthcare Conference at 5:30 P.M. ET (2:30 P.M. PT) on Wednesday, January 14, 2009. The conference is being held at the Westin St. Francis Hotel in San Francisco.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) (vancomycin hydrochloride capsules, USP), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. ViroPharma Provides Update on Vancocin(R)
2. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
3. ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
4. ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008
5. ViroPharma Incorporated Reports Third Quarter 2008 Financial Results
6. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
7. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
8. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
9. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
10. ViroPharma Provides Update on Vancocin(R)
11. ViroPharma Augments Senior Management

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)... -- Sutter Health, a family of doctors, not-for-pr...ders, is donating $255,000 to food banks across No...ill share the quarter-million-dollar donation to h...ds of families across the north state. ,, Sut...nd supporting charitable programs and services. Th...
(Date:11/9/2009)... inhibit estrogen, , , MONDAY, Nov. 9 (...cancer and osteoporosis eliminated cervical cancer... also cleared precancerous growths in the cervix a...ce with precancerous lesions. , The breast canc...osis drug raloxifene were given to mice geneticall...
(Date:11/9/2009)...ons are age-related, researchers say , ,...ry doesn,t appear to speed the progression of age-... new study that challenges the belief that treatin... "Because both conditions are strongly age-related...rote Li Ming Dong, of Stony Brook University Schoo...
(Date:11/9/2009)...stCall/ - Hard To Treat Diseases (HTDS.PK) www.ht...S$41 billion international healthcare company, is ...er, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.... begin a five-year, $1 billion China initiative wi...e its investment in its China R&D facility, an...
(Date:11/9/2009)...rk (NCCN) has posted a draft white paper for publi...erm comparative effectiveness clinical evaluations... the NCCN Comparative Therapeutic Index(TM) (CTI),...versus-benefit of different treatment options reco...n Oncology(TM). The paper will be posted for publi...
Breaking Medicine News(10 mins):Health News:Sutter Health Donates $255,000 to Help the Hungry This Holiday Season 2Health News:Breast Cancer Drugs May Fight Cervical Cancer, Too 2Health News:Cataract Surgery Doesn't Worsen Macular Degeneration: Study 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 2Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 3Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 4
...f news for working couple in India. A study in the...r a year or more tended// to become disruptive in ...e. The finding held up regardless of the chil...te of Child Health and Human Development, recruite...
...rganization (WHO) has approved four new drugs manu... tuberculosis, agency reports say//. And one of th...sistant to standard treatment. The addition ... The medicines are the first TB products to be ad...
..., researchers are discovering that some foods and ...ntion of the modern// world’s deadliest killer- th...erican Chemical Society, a one-day symposium, more...ing cancer of the esophagus, colon — Using animal ...
...he University of California have found out that or... than the ones that are grown// under conventional...agazine Chemistry & Industry. UK environment secre...Amodio and Adel Kader, showed that organically gro...
...iversity of Wisconsin-Madison claim that they can ...eaving out healthy cells//. This is very similar t...ell from another. The new tumor targeting stra...ies and immune responses. "The killing agent we ch...
...Ministry of Thailand plans to set up 21 community ...to relieve the heavy workload of provincial// hosp...ing with patients. The project estimated to c...vongvirot has said that 13 centres will be built i...
Other Medicine News:Health News:Poor Behavior Is Linked to Time in Day Care 2Health News:Indian Pharma Authorized to Market New Anti-TB Drugs 2Health News:Emboldened Warriors-Cancer Fighting Foods 2Health News:Emboldened Warriors-Cancer Fighting Foods 3Health News:organic kiwifruits promote health 2Health News:Tumors Targeted Naturally 2Health News:Tumors Targeted Naturally 3Health News:Hospital Projects to Take the Weight Off Overcrowded Ones 2
(Date:11/9/2009)... Wash., Nov. 9 Cardiac...leader in automated external defibrillator ( AED ...y announced revenue of $38.9 million for the third...s previous guidance. The Company also recorded a c...date and a non-cash charge of $44.0 million to inc...
(Date:11/9/2009)...Mass., Nov. 9 Boston Sci...its schedule of events at the 38th annual Global C...which runs from November 15-19 in Orlando, Florida...nted featuring the Company,s Urology/Gynecology pr...ems and mid-urethral sling systems used to treat p...
(Date:11/9/2009)..., PRINCETON, N.J., Nov. 9 /PRNewswire-FirstCall/...nagement will present at the Sixth Annual Lazard C...ce will be held at the St Regis Hotel in New York ... Pharmasset,s President and Chief Executive Office...esday, November 18, 2009 at 3:45 PM (ET). ,, To...
Breaking Medicine Technology:Cardiac Science Announces Third Quarter Results 2Cardiac Science Announces Third Quarter Results 3Cardiac Science Announces Third Quarter Results 4Cardiac Science Announces Third Quarter Results 5Cardiac Science Announces Third Quarter Results 6Cardiac Science Announces Third Quarter Results 7Cardiac Science Announces Third Quarter Results 8Cardiac Science Announces Third Quarter Results 9Cardiac Science Announces Third Quarter Results 10Cardiac Science Announces Third Quarter Results 11Cardiac Science Announces Third Quarter Results 12Cardiac Science Announces Third Quarter Results 13Cardiac Science Announces Third Quarter Results 14Cardiac Science Announces Third Quarter Results 15Cardiac Science Announces Third Quarter Results 16Cardiac Science Announces Third Quarter Results 17Cardiac Science Announces Third Quarter Results 18Cardiac Science Announces Third Quarter Results 19Cardiac Science Announces Third Quarter Results 20Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 2Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 3Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 4Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 5Pharmasset to Present at Lazard Capital Markets Healthcare Conference 2Pharmasset to Present at Lazard Capital Markets Healthcare Conference 3VitaminSpice Signs MOU With Seamless Corp for Sale of VitaminSpice Product Line on the Seamless Websites 60418 1VitaminSpice Signs MOU With Seamless Corp for Sale of VitaminSpice Product Line on the Seamless Websites 60418 2VitaminSpice Signs MOU With Seamless Corp for Sale of VitaminSpice Product Line on the Seamless Websites 60418 3Therap Services to Host Conference on Electronic Documentation Electronic Signatures and Electronic Health Records for the Developmental Disabilities 60413 1Therap Services to Host Conference on Electronic Documentation Electronic Signatures and Electronic Health Records for the Developmental Disabilities 60413 2London Genetics Focuses on Partnering Following Successful Pharmacogenetics Conference 5884 1London Genetics Focuses on Partnering Following Successful Pharmacogenetics Conference 5884 2London Genetics Focuses on Partnering Following Successful Pharmacogenetics Conference 5884 3London Genetics Focuses on Partnering Following Successful Pharmacogenetics Conference 5884 4
...une 23 Although previous studies,suggest that ort...gth,growth of the eye in children with progressing...yed have been evident. Using a rigorous study desi...con Co., Ltd. and the,Novovision Clinic in Madrid ...ology contact lenses in Spain (MCOS) study to comp...
... Expected to Restart in Second Half 2008, BERKELE...Bulletin Board: GNTA) announced that the Company h...ug Administration (FDA) that,Genta may resume clin...in,Genta,s oncology product portfolio. The notific...sion of a complete response to a prior notice from...
Other Medicine Technology:Menicon Undertakes With the Novovision Clinic a Paediatric Myopia Control Clinical Trial 2FDA Lifts Clinical Hold on Genta's Tesetaxel, a Leading Oral Taxane 2FDA Lifts Clinical Hold on Genta's Tesetaxel, a Leading Oral Taxane 3FDA Lifts Clinical Hold on Genta's Tesetaxel, a Leading Oral Taxane 4
...able laparoscopic 12 mm linear cutting stapler for...ium staples., ,The stapler places two triple, sta... the knife divides the tissue in between. The inst...e surgical procedure: it can be reloaded up to 7 t...
...g unit for reloadable rotating (360°) linear s...tion and anastomosis with titanium staples., ,The...nium staples and simultaneously the knife divides ...for multiple use during a single surgical procedur...
ENDO GIA ROTICULATOR™ (Single Use Loading Units (SULU's) with Titanium Staples)
... Thoracic Endoscopic Linear Cutter has application...urgical procedures for transection, resection, and...taple line buttressing materials such as bovine pe... for a total of eight firings. Different cartridge...
Medicine Products: